This move represented a sharp increase in price on volume nearly 3x the average daily trading volume, indicating robust ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical ...

Scientists have uncovered new evidence showing how type 2 diabetes directly reshapes the human heart, altering both its energy production and physical structure.

"HCM is a heart muscle disease associated with a significant symptom burden. This approval of a new drug, Myqorzo, represents ...

Slated for a Dec. 26 decision on Cytokinetics’ aficamten, the FDA has delivered an early Christmas present, awarding the South San Francisco biotech its first U.S. nod since its 1997 founding. | ...

Now, it’s worth noting Stock Advisor’s total average return is 985 % — a market-crushing outperformance compared to 195% for ...

Scientists develop new blood test to identify individuals at high risk of developing hypertrophic cardiomyopathy, most common ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA ...

These two conditions affect how well your heart can pump blood. Cardiomyopathy can sometimes lead to heart failure. Cardiomyopathy and heart failure are both conditions in which your heart has a more ...

Many people enjoyed the Christmas holiday on December 25th, but it is always extra special for one central Ohio man. On Christmas Day 2015, Dan Leite received a new heart. He was only 50 years old ...